Use App
Trending
News
Earnings
All
DIA
0.64%
SPY
0.15%
QQQ
0.32%
Trending
XLM
32.87%
SPCE
36.64%
HBAR
6.47%
DOGE
1.58%
SMCI
11.36%
XDC
8.66%
BLMN
1.68%
XRP
1.02%
PURR
17.12%
F
4.92%
XLM
32.87%
SPCE
36.64%
HBAR
6.47%
DOGE
1.58%
SMCI
11.36%
XDC
8.66%
BLMN
1.68%
XRP
1.02%
PURR
17.12%
F
4.92%
home
Symbol
RHHBY
news
RHHBY
Roche Holdings AG ADR
3,642
Mkt Cap
$288.8B
Volume
687,526.00
52W High
$60.85
52W Low
$37.51
PE Ratio
21.62
RHHBY Fundamentals
Price
$52.40
Prev Close
$52.36
Open
$52.84
50D MA
$50.65
Beta
0.38
Avg. Volume
2.17M
EPS (Annual)
$2.44
P/B
7.82
Rev/Employee
$656,820.44
$358,793.41
PE Ratio
21.62
Loading...
Loading...
Feed
News
Sentiment
Earnings
Fundamentals
Info
News
all
press releases
Can MRK's New Drugs & Pipeline Aid Long-Term Growth Post Keytruda LOE?
Merck bets on newer drugs, pipeline candidates and M&A deals to offset looming Keytruda patent expiry and drive long-term growth.
Zacks
Share to Feed
More News
How Abbott's Diagnostics Unit Is Shaping Up Through the Rest of 2026
ABT's Diagnostics unit witnesses mixed Q1 results as Core Lab growth offsets China weakness and softer respiratory testing demand.
Zacks
AZN, Daiichi's Enhertu Gets Positive CHMP Opinion for Solid Tumors
AstraZeneca and Daiichi's Enhertu wins CHMP backing for HER2-positive metastatic solid tumors. The camizestrant combo also gains a positive CHMP nod.
Zacks
EXEL Collaborates With MRK for Late-Stage Colorectal Cancer Study
Exelixis teams up with Merck to advance zanzalintinib in a phase III colorectal cancer study, expanding its pipeline beyond Cabometyx.
Zacks
BAYRY or RHHBY: Which Is the Better Value Stock Right Now?
BAYRY vs. RHHBY: Which Stock Is the Better Value Option?
Zacks
AZN, Daiichi's Enhertu Gets FDA Nod for Two New Breast Cancer Settings
AstraZeneca and Daiichi win FDA approval for Enhertu in two new HER2-positive early breast cancer treatment settings.
Zacks
Roche's Tecentriq Wins FDA Nod for Label Expansion in Bladder Cancer
RHHBY wins FDA approval for Tecentriq label expansion as a ctDNA-guided adjuvant therapy for bladder cancer patients at high risk of recurrence.
Zacks
Will Korlym Continue to Aid CORT's Growth in 2026 After a Strong Q1?
Corcept raises 2026 revenue guidance after strong Korlym Q1 performance. New launches and pipeline progress may diversify future growth.
Zacks
How Abbott's Volume-Driven Nutrition Strategy Is Shaping Up
ABT shifts to a volume-led Nutrition strategy with pricing moves and new product launches after Q1 sales declined 6%.
Zacks
Will Keytruda Continue to Aid MRK's Growth in 2026 After a Strong Q1?
Keytruda aids Merck's Q1 performance with $8B in sales. New indications plus combo therapies could fuel the drug's overall growth through 2026.
Zacks
<
1
2
...
>
Compact View
Full View
Mini-Chart
Sentiment
Not available
Message Volume
Not available
Advertisement
|
Remove ads.
Latest RHHBY News
View
Can MRK's New Drugs & Pipeline Aid Long-Term Growth Post Keytruda LOE?
Zacks
How Abbott's Diagnostics Unit Is Shaping Up Through the Rest of 2026
Zacks
AZN, Daiichi's Enhertu Gets Positive CHMP Opinion for Solid Tumors
Zacks
Top Discussions
top
active
trending
Loading...
Advertisement
|
Remove ads.
Watchlist
Trending
News
Explore
Community
Profile